EGFR and non-small cell lung carcinoma: In order to use EGFR TKI, diagnosis by qPCR based on the Cobas® or Therascreen® assay is approved for the detection of EGFR mutations and used routinely, but only Cobas is approved for the use of osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with T790M mutations, and only Therascreen® assay is approved for the use of dacomitinib.